Evidence map›Paper›PMID 36662882›Full record

ArticlePloS one2023

Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function.

Zhenwei Su, Jonathan Brooks, Jeffrey Pelker, Tatyana Andreyeva, Hanna Sobon, Roger Gifford, Matthew Powers, Jing Wang, Corey Dower, Martin Hegen and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Multiscale Computational Dissection of CCRL2-Mediated Chemerin Presentation.Journal of chemical information and modeling · 2025
    Article
  5. Article
  6. Atypical chemokine receptors in the immune system.Nature reviews. Immunology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Zhenwei SuBioMedicine Design, Pfizer, Cambridge, Massachusetts, United States of America.
Jonathan BrooksInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Jeffrey PelkerInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Tatyana AndreyevaInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Hanna SobonInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Roger GiffordInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Matthew PowersInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.
Jing WangBioMedicine Design, Pfizer, Cambridge, Massachusetts, United States of America.
Corey DowerBioMedicine Design, Pfizer, Cambridge, Massachusetts, United States of America.
Martin HegenInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-0883-9076
Dean MessingBioMedicine Design, Pfizer, Cambridge, Massachusetts, United States of America.
Alfredo Darmanin SheehanBioMedicine Design, Pfizer, Dublin, Ireland.
Joseph J BrennanInflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-8939-1583
Pfizer (United States) · USPfizer (Ireland) · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-C motif chemokine receptor-like 2 (CCRL2) is a non-signaling 7 transmembrane receptor that binds chemotactic ligands to shape leukocyte recruitment to sites of inflammation. However, there is a lack of consensus on the ligands that directly bind CCRL2 or their functional impact. Studies with CCRL2 knockout mice have demonstrated that neutrophils have impaired degranulation and migration in response to CXCL8, where the underlying molecular mechanism is proposed to be due to the formation of CCRL2 heterodimers with the chemokine receptor CXCR2. Herein, we characterized the ligands that bind directly to CCRL2 and interrogated the impact of CCRL2 neutralization on CXCL8 signaling in neutrophils using pharmacological antibody tools. Using flow cytometry and Surface Plasmon Resonance microscopy (SPRm) cell binding experiments, we confirmed that chemerin, but not previously reported C-C chemokines, binds CCRL2. Furthermore, we identified human and mouse CCRL2 antibodies that neutralized chemerin binding to CCRL2. Unexpectedly, we found that neutralization of CCRL2 with these antibodies did not attenuate CXCL8-induced human neutrophil degranulation nor CXCL8-induced murine neutrophil recruitment to the peritoneum. Based on the observed differences in modulating CCRL2 function with neutralizing antibodies compared to the reported CCRL2 deficient murine models, we hypothesize that the ligand binding function of CCRL2 is dispensable for CXCL8 signaling in neutrophils. Finally, extensive profiling of CCRL2 expression on peripheral blood leukocytes revealed monocytes, dendritic cells (DC), and subpopulations of natural killer T (NKT) cells as additional targets, highlighting potential roles for CCRL2 in human cell types beyond neutrophils that warrants future investigation.

Indexed as

Neutrophil ActivationReceptors, CCRAnimalsAntibodies, NeutralizingHumansInterleukin-8LigandsMiceNeutrophilsSignal TransductionAntibodies, NeutralizingCcrl2 protein, mouseInterleukin-8LigandsReceptors, CCR

Identifiers

PMID36662882
PMCPMC9858354
OpenAlexW4317602506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.